Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Dual antiplatelet therapy (DAT) is standard post-percutaneous coronary intervention (PCI) due to platelet activation and coagulation cascade following stent placement.
• Stent healing varies: bare metal stents (BMS) re-epithelialize in 6-8 weeks, while drug-eluting stents (DES) have delayed healing, potentially taking months to years for neointima formation.

Purpose of the Study:

• To review the indications, duration, and management of dual antiplatelet therapy (DAT) in patients undergoing percutaneous coronary intervention (PCI).
• To discuss the role of different antiplatelet agents and considerations for surgical management during DAT.

Main Methods:

• Review of current guidelines and clinical practices regarding dual antiplatelet therapy (DAT) after PCI.
• Discussion of pharmacological properties of antiplatelet agents like clopidogrel, prasugrel, ticagrelor, and cangrelor.
• Analysis of factors influencing DAT duration, including stent type, patient thrombotic risk, and surgical interventions.

Main Results:

• DAT duration is typically 3 months for BMS and at least 1 year for DES, with prolonged therapy for high-risk patients.
• DAT continuation is recommended during non-cardiac surgeries if bleeding is controllable and does not compromise surgical outcomes.
• Prasugrel offers advantages over clopidogrel, especially in diabetic patients with acute coronary syndrome undergoing PCI; triple therapy is reserved for specific cases.

Conclusions:

• Optimizing dual antiplatelet therapy (DAT) duration and agent selection is critical for preventing stent thrombosis after PCI.
• Careful consideration of bleeding risk versus thrombotic risk is essential when managing DAT in patients requiring surgery.
• Emerging antiplatelet agents like ticagrelor and cangrelor show promise and are under active clinical investigation.